Nuvalent has revealed compelling phase 1/2 clinical results for its ROS1 inhibitor zidesamtinib, targeting ROS1-positive non-small cell lung cancer patients who failed prior therapies. The drug demonstrated a 44% objective response rate in a pivotal mid-stage study and is positioning for a rolling NDA submission starting next month. Nuvalent aims to address an underserved yet competitive lung cancer niche with a differentiated candidate showing tumor shrinkage and manageable safety. This progress is fueling investor optimism amid plans to expand commercialization efforts in the precision oncology space.